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These results are promising because each 
VLP treatment acted as expected and were 
proved by the negative and positive controls. 
This preliminary data demonstrated the 
potential use of VLPs in targeted drug-
delivery in vitro. My immediate goals 
include conducting similar experiments on 
multiple cell lines, while also teaching my 
fellow lab mates these and other laboratory 
protocols.  As for the team’s future activity, 
pre-clinical trials using zebrafish and mice 
models are part of our overarching goal and 
are being conducted. 
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Muscle atrophy is a debilitating condition that reduces 
quality of life and increases morbidity and mortality. 
Muscle atrophy can occur when an individual is 
bedridden or has an injury  that limits movement. In 
addition, the weakening and eventually the wasting of 
muscle, also known as Cachexia, which affects nearly 
half of all cancer patients and accounts for 20% of 
cancer related deaths (Miller et al., 2019). Cachexia 
results from the excessive breakdown of proteins and 
reduction in  protein synthesis (Cohen et al., 2014). It 
has been demonstrated that maintaining muscle mass 
and function during cancer can significantly improve 
chemotherapy tolerance, quality of life, and prolong 
lifespan (Hiensch et al., 2019). Current treatment for 
cachexia centers around palliative care, but there is no 
treatment for halting or reversing muscle wasting. Our 
long-term goal is to identify potential cell receptors for 
targeted drug delivery pathway in muscle cells. Specific 
goal of this project is to  explore the hypothesis that  
specifically designed Virus Like Particles (VLP 
nanocarriers) can bind to target cell surface receptors 
and deliver their therapeutic cargo into the cells.  
Virus like particles are composed solely of protein 
subunits which self-assemble into the protein shell or 
capsid without viral genetic material. This hollow 
protein shell is uniquely positioned to be suitable for 
cellular entry and release of cargo (Patterson et al, 
2013). For proof of concept, FITC cargo will be 
delivered by receptor-specific VLP constructs to target 
cells in vitro. We will utilize fluorescence imaging 
technology to detect FITC molecules inside the cells in a 
cell culture model of non-human skeletal cells (C2C12) 
as well as human non-muscle cells as negative controls.  
We will address the  hypothesis that  Muscle cells 
containing the target receptors will uptake the VLP 
bearing the specific ligand and carrying FITC 
fluorescent probe, while other cell lines lacking specific 
receptors should fail to incorporate the same constructs.. 
This would prove the concept that VLPs can be used in 
cell- specific drug delivery systems and will be utilized 
in screening potential therapeutics for Cachexia. 
Department of Biology and Biochemistry 
University of Texas at Tyler, Tyler, TX 75799, USA
Mercedes Delgado, Ali Azghani, Dustin Patterson
Application of Virus-Like Particles for Cell-Specific Drug Delivery in vitro 
Treatment Purpose Expected Result Actual Result
T9 (50ng/mL) Directs VLPs to muscle cells Fluoresce green within the cells VLPs delivered the FITC cargo and 
fluoresced green
RGD (50ng/mL) (+) control Fluoresce green within the cells VLPs delivered the FITC cargo and 
fluoresced green
S503c (50ng/mL) (-) control No green fluorescence Cells did not bind with VLPs and 
did not fluoresce green
Using a Cell culture model, with the established 
skeletal muscle cell line C2C12,  a subclone 
(produced by H. Blau, et al) of the mouse 
myoblast cell line established by D. Yaffe and 
O. Saxel. The cells were obtained from the 
American Type Culture Collection (ATCC), 
propagated and stored in Dulbecco's Modified 
Eagle Medium (DMEM) supplemented with 
10% horse serum and incubated at 37ºC with 
5% CO2 gas mixture until they reached 
confluence. Horse serum is a well-known 
growth supplement due to its high content of 
growth promoting factors. The experiment was 
run using 5 cell culture plates with 50,000 cells 
per plate. 
Cells were exposed to genetically engineered 
VLPs derived from the Hong Kong 97 (HK97) 
bacteriophage. There were three VLP treatments 
utilized: T9, RGD, and S503c. The T9 treatment 
is composed of the amino acids 
SKTFNTHPQSTP, which directs VLP to muscle 
tissue. RGD treatment acts as a positive control 
and contains an arginine-glycine-aspartic 
peptide which directs VLP to muscle tissue. The 
S503c VLP treatment contains no peptides and 
should not bind to anything. Exposure time is 30 
minutes to give optimal time for the VLP to 
bind its receptors on to the cells and release its 
cargo, following with 3 successive washes using 
HBSS after. Next, cells will be visualized with 
the ZOE fluorescence imaging system. Pictures 
of each treatment were taken, and the expected 
and actual results were compared and recorded 
(Table 1.0). 
Table 1.0: Expected and actual results of each treatment post-experiment
Each actual treatment result acted as expected. The 
S503c treatment acted as the negative control, which is 
expected to not fluoresce green, and did not fluoresce 
green. The RGD treatment acted as the positive control 
which is expected to fluoresce green and did fluoresce 
green. The T9 treatments targeted VLPs to the cells and 
this treatment did fluorescence green indicating 
successful delivery. (Table 1.0)
Figure 1.0: Depictions of C2C12 skeletal muscle cells post-treatment. Picture A is Treatment T9, picture B is the positive control RGD, and picture C is the negative control S503c post experiment. Green arrows 
represent the cellular reuptake of FITC, seen by green fluorescence, and blue arrows represents the nuclei of the cells. 
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